PHARMACOKINETIC PROOFS ON INTERACTION BETWEEN ZOLPIDEM AND PHENYTOIN: A TWO-TREATMENT, TWO-PERIOD STUDY IN HEALTHY MALE SUBJECTS
DOI:
https://doi.org/10.24193/subbchem.2019.2.33Keywords:
zolpidem; phenytoin; drug interaction; enzymatic inductionAbstract
In clinical practice, the simultaneous use of zolpidem and phenytoin cannot always be avoided, although it can be associated with additive depressants effects on the central nervous system. Considering the common metabolic pathways involving CYP3A and CYP2C, a pharmacokinetic interaction between phenytoin and zolpidem is possible, although not previously quantified. The study was designed as a non-randomized, two-period preclinical trial. Twenty male subjects were included in a study consisting of two periods. Between these, subjects were treated for 6 days with a single daily dose of 150 mg phenytoin. For each treatment period, pharmacokinetic parameters of zolpidem were determined. The multiple-dose administration of phenytoin influenced zolpidem’s pharmacokinetics in healthy volunteers, decreasing its exposure through enzymatic induction.
References
J. MacFarlane, C. M. Morin, J. Montplaisir, Clin Ther., 2014, 36(11), 1676.
Truven Health Analytics. Micromedex® 2.0. Zolpidem. DRUGDEX® Evaluations. Available at: http://www.micromedexsolutions.com/home/dispatch. Accessed February 2017.
E.L. Sutton, Med. Clin. N. Am., 2014, 98, 565.
A. Qaseem, D. Kansagara, M.A. Forciea, et al., Ann. Intern. Med., 2016, 165(2).
J.A. Generali, D.J. Cada, Hosp. Pharm., 2011, 46(2), 101.
R. Ciurleo, P. Bramanti, R.S. Calabrò, Drugs, 2013, 73(17), 1849.
M. Puthiyathu, H. Greenspan, W. Levitt, et al., Psychiatric Annals, 2013, 43(3), 96.
A.C. Fitzgerald, B.T. Wright, S.A. Heldt, Psychopharmacology, 2014, 231, 1865.
Ambien®- zolpidem tartrate tablet, film coated. Sanofi-Aventis U.S. LLC. Drug label information. US National Library of Medicine. DailyMed - official provider of FDA label information. Available at: http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c36cadf4-65a4-4466-b409-c82020b42452. Accessed November 2015.
L.L. von Moltke, D.J. Greenblatt, B.W. Granda, et al., Br. J. Clin. Pharmacol., 1999, 48(1), 89.
M. Bialer, Epilepsia, 2012, 53(7), 26.
Agence nationale de sécurité du médicament et des produits de santé. Résumé des caractéristiques du produit Di-Hydan® 100 mg, comprimé sécable. Available at: http://base-donnees-publique.medicaments.gouv.fr/affichageDoc.php?specid=
&typedoc=R. Accessed February 2017.
H. Torbic, A.A. Forni, K.E. Anger, et al., Am. J. Health. Syst. Pharm., 2013, 70(9), 759.
R. Bauer, M. Ortler, M. Seiz-Rosenhagen, et al., Neurosurg. Rev., 2014, 37(3), 381.
G.L. Birbeck, J.A. French, E Perucca, et al., Epilepsia, 2012, 53(1), 207.
J.O. McNamara, Pharmacotherapy of the Epilepsies. In L. Brunton, J. Lazo, K. Parker, Eds. Goodman & Gilman's The pharmacological basis of therapeutics. 11th ed. New York: The McGraw-Hill Companies, Inc; 2005. Chapter 19.
Truven Health Analytics. Micromedex® 2.0. Phenytoin. DRUGDEX® Evaluations. Available at: http://www.micromedexsolutions.com/home/dispatch. Accessed February 2017.
J. Tanaka, H. Kasai, K. Shimizu, et al., Eur. J. Clin. Pharmacol., 2013, 69(3), 489.
P.N. Patsalos, D.J. Berry, B.F. Bourgeois, et al., Epilepsia, 2008, 49(7), 1239.
R.J. Porter, B.S. Meldrum, Antiseizure Drugs. In B.G. Katzung, S.B. Masters, A.J.Trevor Basic & Clinical Pharmacology, 12th ed. New York: The McGraw-Hill Companies, Inc; 2012. Chapter 24.
C. Hiemke, P. Baumann, N. Bergemann, et al., Pharmacopsychiatry, 2011, 44(6), 195.
M.D. Krasowski, L.E. Penrod, BMC Medical Informatics and Decision Making, 2012, 12, 7.
A. Galetin, M. Gertz, J.B.Houston, Drug. Metab. Pharmacokinet., 2010, 25(1), 28.
I. Cascorbi, Dtsch. Arztebl. Int., 2012, 109(33–34), 546.
T. Roehrs, T. Roth, Neurotherapeutics, 2012, 9, 728.
M. Quigg, S. Gharai, J. Ruland, et al., Epilepsy Res., 2016, 122, 91.
M.D. Cheatle, S. Foster, A. Pinkett, et al., Anesthesiology Clin. 2016, 34, 379.
N. Gunja, J. Med. Toxicol., 2013, 9, 155.
M.J. Brodie, S. Mintzer, A.M. Pack, et al., Epilepsia, 2013, 54(1), 11.
C. Gurudeva, P.A. Patil, S.V. Hiremath, et al., Pharmacologyonline, 2008, 3, 978.
K. Villikka, K.T. Kivistö, H. Luurila, et al., Clin Pharmacol. Ther., 1997, 62(6), 629.
Y. Hojo, M. Echizenya, T. Ohkubo, et al., J Clin Pharm Ther., 2011, 36(6), 711.
J.F. Okulicz, G.A. Grandits, J.A. French, et al., Epilepsy Res., 2013, 103(2-3), 245.
W.K. Kennedy, M.W. Jann, E.C. Kutscher, CNS Drugs, 2013, 27(12), 1021.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2019 Studia Universitatis Babeș-Bolyai Chemia
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
